MTNB - MCAP CO - Matinas BioPharma

The Matinas BioPharma (MTNB) business model is based on innovations for converting injectable drugs into oral forms. This price chart demonstrates an asset with a market capitalization of 0.00. The use of lipid nanocrystals for drug protection allows the company to exercise pricing power regarding licensing costs. The company is currently in the clinical trial stage; consequently, it generates no commercial revenue, and scaling operations only increases laboratory research expenditures.

Market capitalization determines the total value of a company's equity at the current moment. By analyzing the total capitalization of a public company, an investor sees the product of the current share price and the total number of outstanding shares. The current value of this metric is 0.00. The dynamics of this indicator reflect market confidence in the assets. For Matinas BioPharma (MTNB), the valuation depends directly on the success of the LNC platform and the trial results of oral amphotericin B.